(Total Views: 598)
Posted On: 05/11/2021 5:40:16 AM
Post# of 154104
Sure.. there's classic and then there's modern day. I don't think any bashers on these boards are going out and complaining in Tagalog to any Filipino that will listen lies about LLMab being too expensive and unobtainable.. that's not directly aimed at investors, that's to attempt to stifle adoption. Modern day stuff.
It's the ones on the boards, saying that CytoDyn can't make any money off LLMab, the "competition" is too cheap, etc.. there is no competition and cost to manufacture per dose is guaranteed to profit. They know they can't say "it doesn't work" for much longer, so strategy shifts... Like if Nader rejected the low-ball buyout offer, now they're trying to lower expectations so a $20-$30 offer seems reasonable, which, it isn't. That's classic.. "you'll never be worth that."
We will.
It's the ones on the boards, saying that CytoDyn can't make any money off LLMab, the "competition" is too cheap, etc.. there is no competition and cost to manufacture per dose is guaranteed to profit. They know they can't say "it doesn't work" for much longer, so strategy shifts... Like if Nader rejected the low-ball buyout offer, now they're trying to lower expectations so a $20-$30 offer seems reasonable, which, it isn't. That's classic.. "you'll never be worth that."
We will.
(8)
(0)
